Amgen teams up with Merck on melanoma treatments
Thousand Oaks-based Amgen and pharmaceutical giant Merck are working together to evaluate the safety and effectiveness of combined treatments for melanoma patients.
Amgen profits hit $5B, beat expectations
The biotech company recorded earnings per share of $7.60, well above the $7.46 expected by a survey of 27 analysts by Thomson Reuters.
Amgen reports positive trial results for high-cholesterol treatment
The portion of Amgen’s Phase 3 trial of evolocumab that evaluated patients with high cholesterol who cannot tolerate statins has met goals related to percent reduction of low-density lipoprotein cholesterol.
Amgen enters into deals for colon cancer, IBD treatments
Thousand Oaks-based Amgen has entered into two new collaborations, one involving treatment for colon cancer and another regarding therapies for inflammatory bowel disease.
Round 2: Atara raises $13.5M as T.O. biotech boom takes hold
Thousand Oaks-based Atara Biotherapeutics has brought on more investors to its second financing round, bringing the total raised to $52 million.
Amgen’s chief financial officer to depart
Chief Financial Officer Jonathan M. Peacock is leaving Amgen to pursue broader career opportunities, the company announced. Michael A. Kelly has been named acting CFO.
